Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation.

Schüring AN, Fehm T, Behringer K, Goeckenjan M, Wimberger P, Henes M, Henes J, Fey MF, von Wolff M.

Arch Gynecol Obstet. 2018 Jan;297(1):241-255. doi: 10.1007/s00404-017-4594-3. Epub 2017 Nov 24.

2.

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S, Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A, Pabst T, Giagounidis A, Kobbe G, Wollmer E, Finke J, Neubauer A, Burchert A.

Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18.

PMID:
29055209
3.

The costs of care in haematological cancers: Health economic issues.

Fey MF.

Hematol Oncol. 2017 Jun;35 Suppl 1:15-19. doi: 10.1002/hon.2394. No abstract available.

PMID:
28591414
4.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

5.

MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.

Rothschild SI, Gautschi O, Batliner J, Gugger M, Fey MF, Tschan MP.

Lung Cancer. 2017 May;107:73-83. doi: 10.1016/j.lungcan.2016.06.004. Epub 2016 Jun 14.

PMID:
27372519
6.

The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation.

Wampfler J, Federzoni EA, Torbett BE, Fey MF, Tschan MP.

Leuk Res. 2016 Feb;41:96-102. doi: 10.1016/j.leukres.2015.12.006. Epub 2015 Dec 19.

PMID:
26740055
7.

Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.

Wampfler J, Federzoni EA, Torbett BE, Fey MF, Tschan MP.

J Leukoc Biol. 2015 Sep;98(3):357-63. doi: 10.1189/jlb.1AB0514-258R. Epub 2015 May 19.

8.

Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells.

Federzoni EA, Gloor S, Jin J, Shan-Krauer D, Fey MF, Torbett BE, Tschan MP.

Leuk Res Rep. 2015 Apr 23;4(1):32-5. doi: 10.1016/j.lrr.2015.04.002. eCollection 2015.

9.

[Today's cancer medicine: less could often be more].

Fey MF.

Ther Umsch. 2014 Dec;71(12):765-70. doi: 10.1024/0040-5930/a000623. Review. German.

PMID:
25447092
10.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
11.

Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.

Vidal AD, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE.

Ann Oncol. 2015 Feb;26(2):374-7. doi: 10.1093/annonc/mdu518. Epub 2014 Nov 12.

PMID:
25392157
12.

Induction of the autophagy-associated gene MAP1S via PU.1 supports APL differentiation.

Haimovici A, Brigger D, Torbett BE, Fey MF, Tschan MP.

Leuk Res. 2014 Sep;38(9):1041-7. doi: 10.1016/j.leukres.2014.06.010. Epub 2014 Jul 1.

PMID:
25043887
13.

Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.

Bohlius J, Tonia T, Nüesch E, Jüni P, Fey MF, Egger M, Bernhard J.

Br J Cancer. 2014 Jul 8;111(1):33-45. doi: 10.1038/bjc.2014.171. Epub 2014 Apr 17. Review.

14.

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation.

Federzoni EA, Humbert M, Torbett BE, Behre G, Fey MF, Tschan MP.

Sci Rep. 2014 Mar 3;4:4261. doi: 10.1038/srep04261.

15.

Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.

Stutz E, Gautschi O, Fey MF, Gugger M, Tschan MP, Rothschild SI.

Future Oncol. 2014 Feb;10(2):211-7. doi: 10.2217/fon.13.179.

PMID:
24490607
16.

The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL.

Humbert M, Federzoni EA, Britschgi A, Schläfli AM, Valk PJ, Kaufmann T, Haferlach T, Behre G, Simon HU, Torbett BE, Fey MF, Tschan MP.

J Leukoc Biol. 2014 Jan;95(1):83-93. doi: 10.1189/jlb.1112608. Epub 2013 Sep 13.

17.

Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Fey MF, Buske C; ESMO Guidelines Working Group.

Ann Oncol. 2013 Oct;24 Suppl 6:vi138-43. doi: 10.1093/annonc/mdt320. Epub 2013 Aug 22. No abstract available.

PMID:
23970018
18.

Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.

Brigger D, Torbett BE, Chen J, Fey MF, Tschan MP.

Biochem Biophys Res Commun. 2013 Aug 23;438(2):283-8. doi: 10.1016/j.bbrc.2013.07.056. Epub 2013 Jul 24.

19.

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

Humbert M, Medová M, Aebersold DM, Blaukat A, Bladt F, Fey MF, Zimmer Y, Tschan MP.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):264-9. doi: 10.1016/j.bbrc.2012.12.120. Epub 2013 Jan 9.

PMID:
23313490
20.

The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.

Federzoni EA, Humbert M, Valk PJ, Behre G, Leibundgut EO, Torbett BE, Fey MF, Tschan MP.

Br J Haematol. 2013 Mar;160(6):855-9. doi: 10.1111/bjh.12170. Epub 2012 Dec 17. No abstract available.

PMID:
23252456
21.

BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation.

Schläfli AM, Torbett BE, Fey MF, Tschan MP.

Exp Hematol Oncol. 2012 Sep 4;1(1):25. doi: 10.1186/2162-3619-1-25.

22.

Inhibition of damage-regulated autophagy modulator-1 (DRAM-1) impairs neutrophil differentiation of NB4 APL cells.

Humbert M, Mueller C, Fey MF, Tschan MP.

Leuk Res. 2012 Dec;36(12):1552-6. doi: 10.1016/j.leukres.2012.08.024. Epub 2012 Sep 13.

PMID:
22981223
23.

MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma.

Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M, Gautschi O.

J Thorac Oncol. 2012 Jul;7(7):1069-77. doi: 10.1097/JTO.0b013e31824fe976.

24.

PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.

Federzoni EA, Valk PJ, Torbett BE, Haferlach T, Löwenberg B, Fey MF, Tschan MP.

Blood. 2012 May 24;119(21):4963-70. doi: 10.1182/blood-2011-09-378117. Epub 2012 Apr 12.

25.

MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.

Rothschild SI, Tschan MP, Federzoni EA, Jaggi R, Fey MF, Gugger M, Gautschi O.

Oncogene. 2012 Sep 20;31(38):4221-32. doi: 10.1038/onc.2011.578. Epub 2012 Jan 16.

PMID:
22249264
26.

Autophagy is required for self-renewal and differentiation of adult human stem cells.

Salemi S, Yousefi S, Constantinescu MA, Fey MF, Simon HU.

Cell Res. 2012 Feb;22(2):432-5. doi: 10.1038/cr.2011.200. Epub 2011 Dec 20. No abstract available.

27.

Marriage risk of cancer research fellows.

Fey MF, Tobler A.

Lancet. 2011 Dec 17;378(9809):2070. doi: 10.1016/S0140-6736(11)61898-9. No abstract available.

PMID:
22177511
28.

Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells.

Batliner J, Buehrer E, Federzoni EA, Jenal M, Tobler A, Torbett BE, Fey MF, Tschan MP.

Br J Haematol. 2012 Apr;157(2):270-4. doi: 10.1111/j.1365-2141.2011.08964.x. Epub 2011 Dec 7. No abstract available.

PMID:
22145969
29.

Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells.

Batliner J, Buehrer E, Fey MF, Tschan MP.

Leuk Res. 2012 Feb;36(2):237-40. doi: 10.1016/j.leukres.2011.10.006. Epub 2011 Nov 16.

PMID:
22093444
30.

[Recombinant proteins as therapeutic compounds in clinical oncology].

Fey MF.

Ther Umsch. 2011 Nov;68(11):618-30. doi: 10.1024/0040-5930/a000222. Review. German.

PMID:
22045524
31.

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK).

Blood. 2011 Dec 1;118(23):6037-42. doi: 10.1182/blood-2011-07-370247. Epub 2011 Sep 27.

32.

Deregulated expression of Kruppel-like factors in acute myeloid leukemia.

Humbert M, Halter V, Shan D, Laedrach J, Leibundgut EO, Baerlocher GM, Tobler A, Fey MF, Tschan MP.

Leuk Res. 2011 Jul;35(7):909-13. doi: 10.1016/j.leukres.2011.03.010. Epub 2011 Apr 5.

PMID:
21470678
33.

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.

Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O.

Support Care Cancer. 2012 Jan;20(1):141-7. doi: 10.1007/s00520-010-1079-3. Epub 2011 Jan 14.

PMID:
21234609
34.

Inactivation of the hypermethylated in cancer 1 tumour suppressor--not just a question of promoter hypermethylation?

Jenal M, Britschgi C, Fey MF, Tschan MP.

Swiss Med Wkly. 2010 Nov 1;140:w13106. doi: 10.4414/smw.2010.13106. eCollection 2010. Review.

35.

CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.

Batliner J, Mancarelli MM, Jenal M, Reddy VA, Fey MF, Torbett BE, Tschan MP.

Mol Immunol. 2011 Jan;48(4):714-9. doi: 10.1016/j.molimm.2010.10.016. Epub 2010 Nov 20.

36.

[Lymphoma--a topic with seven seals].

Fey MF.

Ther Umsch. 2010 Oct;67(10):489. German. No abstract available.

PMID:
21046824
37.

[Salient clinical features of lymphoma and related lymphoproliferative disorders].

Fey MF.

Ther Umsch. 2010 Oct;67(10):491-5. doi: 10.1024/0040-5930/a000083. German.

PMID:
20886453
38.

Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Fey MF, Dreyling M; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v158-61. doi: 10.1093/annonc/mdq179. No abstract available.

39.

The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1.

Jenal M, Batliner J, Reddy VA, Haferlach T, Tobler A, Fey MF, Torbett BE, Tschan MP.

Leukemia. 2010 May;24(5):1073-6. doi: 10.1038/leu.2010.26. Epub 2010 Mar 4. No abstract available.

PMID:
20200559
40.

Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2.

Britschgi A, Simon HU, Tobler A, Fey MF, Tschan MP.

Br J Haematol. 2010 Apr;149(1):55-64. doi: 10.1111/j.1365-2141.2009.08040.x. Epub 2010 Jan 20.

PMID:
20096012
41.

NDRG1/2 expression is inhibited in primary acute myeloid leukemia.

Tschan MP, Shan D, Laedrach J, Eyholzer M, Leibundgut EO, Baerlocher GM, Tobler A, Stroka D, Fey MF.

Leuk Res. 2010 Mar;34(3):393-8. doi: 10.1016/j.leukres.2009.08.037. Epub 2009 Sep 22.

PMID:
19775754
42.

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007303. doi: 10.1002/14651858.CD007303.pub2. Review.

43.

The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1.

Jenal M, Trinh E, Britschgi C, Britschgi A, Roh V, Vorburger SA, Tobler A, Leprince D, Fey MF, Helin K, Tschan MP.

Mol Cancer Res. 2009 Jun;7(6):916-22. doi: 10.1158/1541-7786.MCR-08-0359. Epub 2009 Jun 2.

44.

SIRT1 is downregulated during neutrophil differentiation of acute promyelocytic leukaemia cells.

Wampfler J, Tschan MP, Shan D, Laemmle A, Leibundgut EO, Baerlocher GM, Stroka D, Fey MF, Britschgi C.

Br J Haematol. 2009 Aug;146(3):337-41. doi: 10.1111/j.1365-2141.2009.07749.x. Epub 2009 May 19. No abstract available.

PMID:
19466968
45.

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.

Lancet. 2009 May 2;373(9674):1532-42. doi: 10.1016/S0140-6736(09)60502-X. Erratum in: Lancet. 2009 Jul 4-2009 Jul 10;374(9683):28.

PMID:
19410717
46.

Induction of Bim limits cytokine-mediated prolonged survival of neutrophils.

Andina N, Conus S, Schneider EM, Fey MF, Simon HU.

Cell Death Differ. 2009 Sep;16(9):1248-55. doi: 10.1038/cdd.2009.50. Epub 2009 May 1.

47.

Tumor suppressor genes in myeloid differentiation and leukemogenesis.

Britschgi C, Fey MF.

Future Oncol. 2009 Mar;5(2):245-57. doi: 10.2217/14796694.5.2.245. Review.

PMID:
19284382
48.

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG).

Breast Cancer Res Treat. 2009 Sep;117(2):319-24. doi: 10.1007/s10549-008-0282-0. Epub 2009 Jan 10.

49.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.

50.

New insights into molecular mechanisms of haematological malignancies.

Fey MF.

Ann Oncol. 2008 Jul;19 Suppl 5:v59-62. doi: 10.1093/annonc/mdn312. Review. No abstract available.

Supplemental Content

Support Center